Genmab — December 2020
-
God morgen
-
Hvor stort er Epcoritamabs marked? Hvis man ser på side 19 i vedlagte, så er Epcoritamabs potentielle marked større end Darzalex (DLBCL, FL of
-
og MCL). Så overgår Epcoritamabs potentielle marked Darzalex‘s https://ir.genmab.com/static-files/01719d81-5070-4520-a694-4fc1585da826
-
Så de 4 milliarder $ som Verdult skønner, kan blive meget mere (selvfølgelig under forudsætning af at Epcoritamab bliver best in class)
-
Nu afhænger det selvfølgelig og af duration of treatment, men det virker som Epcoritamab kan fotlænge duration ganske meget i forhold til nuværende SOC
-
Genmab satser også på at Epcoritamab kan få en rolle i CLL. Muligheder en masse...
-
SVB Leerink cuts price target on Genmab to $ 34 from $ 36 - Reuters News
-
DDB: We believe the ASH data were close to a best-case outcome for epcoritamab with
efficacy on par with best responses seen from competitors. The safety profile
remains benign clearing the way for frontline therapy in multiple indications and
multi-blockbuster potential. We keep Hold but lift 12M target price to DKK2,600. -
Danske Bank: "Valuation. Our updated sum-of-the-parts now points to a fair value of DKK2,638 (DKK2,467) following the ASH conference, primarily reflecting more value for epcoritamab (DKK558 vs DKK405) with the supportive data presented. We now see a potential USD10bn in peak sales with the potential in frontline NHL/CLL."
-
Potential 10 billion $ peak sale...
-
Jeg må le, giver absolut ingen mening, alt under 3000 er en joke for nuværende, I januar kommer de til at guide for BB i $ for Dara og samtidig burde værdien af epco stige væsentlig mere i forhold til risikovurderingsprofil. Salget i Tepro og Ofa vil stige progressivt, måske endda ekspotentielt. Et 12 mdr. target på 2600 er ikke et pletskud fra OBH, nærmere et totalt mis på dartskiven.
-
Phase 1 Results of Teclistamab, BCMA Alfred L. Garfall, MD, MS of the Hospital of the University of Pennsylvania https://www.oncologytube.com/video/39636/alfred-l.-garfall-md-ms-algarfall-pennmednews-ash20-bcma-rrmm-cancer-research-phase-1-results-of-teclistamab-bcma
-
@GB, "sjovt" med SVB Leerink - det seneste kursmål jeg har OG kan finde på nettet er $35 og ikke $34: https://thefly.com/landingPageNews.php?id=3156715&headline=GMAB-Genmab-initiated-with-a-Market-Perform-at-SVB-Leerink
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind